ReviewLeukemia & lymphoma2016
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Review in Leukemia & lymphoma, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 83 citations in OpenAlex.
- Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.Annals of hematology · 2022Trial
- Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- A multicenter, single-arm, Phase II clinical trial of bendamustine monotherapy in patients with chronic lymphocytic leukemia in Japan.International journal of hematology · 2017Trial
- Equecabtagene autoleucel as sequential therapy in a multiple myeloma patient with renal failure: a case report.Frontiers in medicine · 2026Article
- Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma.Blood neoplasia · 2024Article
- Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.Blood advances · 2024Observational
- [Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.Investigational new drugs · 2023Article
- Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.Journal of cancer research and clinical oncology · 2023Article
- Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.Frontiers in immunology · 2023Review
- Novel 1,2,5-Trisubstituted Benzimidazoles Potentiate Apoptosis by Mitochondrial Dysfunction in Panel of Cancer Cells.ACS omega · 2022Article
- Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).Oncology reports · 2022Review
- Bendamustine and pneumocystis pneumonia: A systematic review.Health science reports · 2022Review
- Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine.Cancer medicine · 2021Observational
- Current Treatment Options in CLL.Cancers · 2021Review
- Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia.Journal of personalized medicine · 2021Article
- How do I sequence therapy for follicular lymphoma?Hematology. American Society of Hematology. Education Program · 2020Review
- A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies.Clinical lymphoma, myeloma & leukemia · 2020Article
- Article
- Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.Haematologica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.